Literature DB >> 28336086

Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.

Lindsay Joy Spielman1, Deanna Lynn Gibson2, Andis Klegeris3.   

Abstract

The incretin hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) are primarily known for their metabolic function in the periphery. GLP-1 and GIP are secreted by intestinal endocrine cells in response to ingested nutrients. Both GLP-1 and GIP stimulate the production and release of insulin from pancreatic β cells as well as exhibit several growth-regulating effects on peripheral tissues. GLP-1 and GIP are also present in the brain, where they provide modulatory and anti-apoptotic signals to neurons. However, very limited information is available regarding the effects of these hormones on glia, the immune and supporting cells of the brain. Therefore, we set out to resolve whether primary human microglia and astrocytes, two subtypes of glial cells, express the GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), which are necessary to detect and respond to GLP-1 and GIP, respectively. We further tested whether these hormones, similar to their effects on neuronal cells, have growth-regulating, antioxidant and anti-apoptotic effects on microglia. We show for the first time expression of the GLP-1R and the GIPR by primary human microglia and astrocytes. We demonstrate that GLP-1 and GIP reduce apoptotic death of murine BV-2 microglia through the binding and activation of the GLP-1R and GIPR, respectively, with subsequent activation of the protein kinase A (PKA) pathway. Moreover, we reveal that incretins upregulate BV-2 microglia expression of brain derived neurotrophic factor (BDNF), glial cell-line derived neurotrophic factor (GDNF) and nerve growth factor (NGF) in a phosphoinositide 3-kinase (PI3K)- and PKA-dependent manner. We also show that incretins reduce oxidative stress in BV-2 microglia by inhibiting the accumulation of intracellular reactive oxygen species (ROS) and release of nitric oxide (NO), as well as by increasing the expression of the antioxidant glutathione peroxidase 1 (GPx1) and superoxide dismutase 1 (SOD1). We confirm these results by demonstrating that GLP-1 and GIP also inhibit apoptosis of primary murine microglia, and upregulate expression of BDNF by primary murine microglia. These results indicate that GLP-1 and GIP affect several critical homeostatic functions of microglia, and could therefore be tested as a novel therapeutic treatment option for brain disorders that are characterized by increased oxidative stress and microglial degeneration.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Apoptosis; Cell death; Incretins; Microglia degeneration; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28336086     DOI: 10.1016/j.ejcb.2017.03.004

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  20 in total

Review 1.  Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease.

Authors:  Dong Dong; Junxia Xie; Jun Wang
Journal:  Neurosci Bull       Date:  2019-07-08       Impact factor: 5.203

Review 2.  The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.

Authors:  Qi N Cui; Lauren M Stein; Samantha M Fortin; Matthew R Hayes
Journal:  Br J Pharmacol       Date:  2021-11-23       Impact factor: 8.739

Review 3.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

Review 4.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

5.  Inflammatory and cytotoxic effects of bifenthrin in primary microglia and organotypic hippocampal slice cultures.

Authors:  Brahim Gargouri; Nizar M Yousif; Michèle Bouchard; Hamadi Fetoui; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2018-05-24       Impact factor: 8.322

6.  Modulation of microglial functions by methyl jasmonate.

Authors:  Jordan A McKenzie; Andis Klegeris
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

7.  The Promising Effects of Transplanted Umbilical Cord Mesenchymal Stem Cells on the Treatment in Traumatic Brain Injury.

Authors:  Lifeng Qi; Xinhong Xue; Jijun Sun; Qingjian Wu; Hongru Wang; Yan Guo; Baoliang Sun
Journal:  J Craniofac Surg       Date:  2018-10       Impact factor: 1.046

8.  The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.

Authors:  Makoto Ide; Noriyuki Sonoda; Tomoaki Inoue; Shinichiro Kimura; Yohei Minami; Hiroaki Makimura; Eiichi Hayashida; Fuminori Hyodo; Mayumi Yamato; Ryoichi Takayanagi; Toyoshi Inoguchi
Journal:  PLoS One       Date:  2020-02-07       Impact factor: 3.240

9.  A unique hybrid characteristic having both pro- and anti-inflammatory phenotype transformed by repetitive low-dose lipopolysaccharide in C8-B4 microglia.

Authors:  Haruka Mizobuchi; Kazushi Yamamoto; Shoko Tsutsui; Masafumi Yamashita; Yoko Nakata; Hiroyuki Inagawa; Chie Kohchi; Gen-Ichiro Soma
Journal:  Sci Rep       Date:  2020-06-02       Impact factor: 4.379

Review 10.  The gut microbiota to the brain axis in the metabolic control.

Authors:  Estelle Grasset; Remy Burcelin
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.